Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | CPA1 | P15085 | 2/20 | 0.46 |
| ▸ | CPA3 | P15088 | 2/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | CPB1 | P15086 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17995281 | 0.84 | CYP1A2 (0.68) | CYP1A2MMECPA1CPA3FOLH1 | |
| SCHEMBL26521147 | 0.83 | CYP1A2 (0.55) | CYP1A2NPC1RAB9AMMELTA4H | |
| SCHEMBL18623970 | 0.79 | CYP1A2 (0.55) | CYP1A2NPC1RAB9AMMELTA4H | |
| SCHEMBL19483349 | 0.79 | ANPEP (0.55) | CYP1A2NPC1RAB9AMMECPA1 | |
| SCHEMBL19483376 | 0.78 | CYP1A2 (0.53) | CYP1A2NPC1RAB9AMMELTA4H | |
| SCHEMBL28411865 | 0.78 | CYP1A2 (0.53) | CYP1A2NPC1RAB9AMMELTA4H | |
| SCHEMBL7428869 | 0.78 | EPHX2 (0.56) | CYP1A2NPC1 | |
| SCHEMBL13165582 | 0.78 | CYP1A2 (0.49) | CYP1A2NPC1RAB9AMMELTA4H | |
| SCHEMBL17087653 | 0.77 | CYP1A2 (0.52) | CYP1A2NPC1RAB9AMMECPA1 | |
| SCHEMBL14640223 | 0.76 | TAAR1 (0.53) | CYP1A2NPC1RAB9AMMECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210221848-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221848-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | PNISR, MRPS18A, MRPS35 | CYP1A2 3479/4885NPC1 4455/4885RAB9A 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.